Hideyuki Abe

920 total citations
39 papers, 739 citations indexed

About

Hideyuki Abe is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Hideyuki Abe has authored 39 papers receiving a total of 739 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Hideyuki Abe's work include Renal cell carcinoma treatment (12 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Hideyuki Abe is often cited by papers focused on Renal cell carcinoma treatment (12 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Hideyuki Abe collaborates with scholars based in Japan and United States. Hideyuki Abe's co-authors include Takao Kamai, Ken‐Ichiro Yoshida, Kyoko Arai, Akinori Masuda, Hiromichi Shirataki, Akinori Nukui, Tomoya Mizuno, Hironori Betsunoh, Tetsunari Oyama and Masahiro Yashi and has published in prestigious journals such as International Journal of Molecular Sciences, International Journal of Cancer and BioMed Research International.

In The Last Decade

Hideyuki Abe

38 papers receiving 730 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hideyuki Abe Japan	16	362	246	227	154	107	39	739
Cuiju Tang China	14	382 1.1×	340 1.4×	240 1.1×	178 1.2×	81 0.8×	47	853
Michio Kosugi Japan	15	427 1.2×	175 0.7×	178 0.8×	136 0.9×	100 0.9×	27	787
Fumiko Chiwaki Japan	16	465 1.3×	179 0.7×	156 0.7×	178 1.2×	84 0.8×	27	718
Walid J. Azar Australia	11	480 1.3×	254 1.0×	190 0.8×	262 1.7×	56 0.5×	11	827
Omar Moussa United States	19	423 1.2×	140 0.6×	145 0.6×	203 1.3×	33 0.3×	25	828
Tomohiro Sakuma Japan	17	356 1.0×	282 1.1×	213 0.9×	253 1.6×	92 0.9×	23	796
Frédéric Commo France	13	247 0.7×	273 1.1×	226 1.0×	171 1.1×	104 1.0×	16	774
Andrea Laforme United States	9	432 1.2×	154 0.6×	118 0.5×	258 1.7×	78 0.7×	9	805
Françoise Descôtes France	20	593 1.6×	342 1.4×	154 0.7×	326 2.1×	247 2.3×	66	1.2k
Robert Cummins Ireland	20	487 1.3×	399 1.6×	334 1.5×	220 1.4×	151 1.4×	46	1.1k

Countries citing papers authored by Hideyuki Abe

Since Specialization

Citations

This map shows the geographic impact of Hideyuki Abe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideyuki Abe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideyuki Abe more than expected).

Fields of papers citing papers by Hideyuki Abe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideyuki Abe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideyuki Abe. The network helps show where Hideyuki Abe may publish in the future.

Co-authorship network of co-authors of Hideyuki Abe

This figure shows the co-authorship network connecting the top 25 collaborators of Hideyuki Abe. A scholar is included among the top collaborators of Hideyuki Abe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideyuki Abe. Hideyuki Abe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kamai, Takao, Toshiki Kijima, Toyonori Tsuzuki, et al.. (2021). Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival. Cancer Immunology Immunotherapy. 70(7). 2009–2021. 33 indexed citations

Kobayashi, Minoru, Tomoya Mizuno, Hironori Betsunoh, et al.. (2019). Association between serum prostate-specific antigen level and diabetes, obesity, hypertension, and the laboratory parameters related to glucose tolerance, hepatic function, and lipid profile: implications for modification of prostate-specific antigen threshold. International Journal of Clinical Oncology. 25(3). 472–478. 15 indexed citations

Nukui, Akinori, Takahiro Narimatsu, Hideyuki Abe, et al.. (2018). Clinically significant association of elevated expression of nuclear factor E2-related factor 2 expression with higher glucose uptake and progression of upper urinary tract cancer. BMC Cancer. 18(1). 493–493. 5 indexed citations

Yashi, Masahiro, Akinori Nukui, Issei Suzuki, et al.. (2017). Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy. BMC Urology. 17(1). 47–47. 4 indexed citations

Nukui, Akinori, Akinori Masuda, Hideyuki Abe, et al.. (2017). Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy. BMC Cancer. 17(1). 372–372. 21 indexed citations

Abe, Hideyuki, Issei Suzuki, Kazumasa Sakamoto, et al.. (2017). Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy. International Journal of Clinical Oncology. 23(2). 338–346. 14 indexed citations

Nukui, Akinori, Yoshiaki Yanai, Toyonori Tsuzuki, et al.. (2017). Germline polymorphism of interferon-lambda3 is clinically associated with progression of renal cell carcinoma. Oncotarget. 9(3). 4188–4199. 2 indexed citations

Masuda, Akinori, Kyoko Arai, Tomoya Mizuno, et al.. (2014). Clinical Significance of Serum Soluble T Cell Regulatory Molecules in Clear Cell Renal Cell Carcinoma. BioMed Research International. 2014. 1–6. 20 indexed citations

Yashi, Masahiro, Tomoya Mizuno, Akinori Masuda, et al.. (2014). Prostate volume and biopsy tumor length are significant predictors for classical and redefined insignificant cancer on prostatectomy specimens in Japanese men with favorable pathologic features on biopsy. BMC Urology. 14(1). 43–43. 10 indexed citations

10.

Yashi, Masahiro, Tomoya Mizuno, Akinori Masuda, et al.. (2014). Metronomic Oral Cyclophosphamide Chemotherapy Possibly Contributes to Stabilization of Disease in Patients With Metastatic Castration-Resistant Prostate Cancer: A Prospective Analysis of Consecutive Cases. Clinical Genitourinary Cancer. 12(5). e197–e203. 13 indexed citations

11.

Abe, Hideyuki, Takao Kamai, Keitaro Hayashi, et al.. (2014). The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells. BMC Cancer. 14(1). 412–412. 34 indexed citations

12.

Betsunoh, Hironori, Naohiko Anzai, Tomoya Mizuno, et al.. (2013). Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma. BMC Cancer. 13(1). 509–509. 65 indexed citations

13.

Kamai, Takao, Hiromichi Shirataki, Yoshiaki Yanai, et al.. (2011). Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma. Cancer Immunology Immunotherapy. 60(6). 793–808. 16 indexed citations

14.

Kamai, Takao, Hideyuki Abe, Mikihiko Honda, et al.. (2010). Single minimum incision endoscopic radical nephrectomy for renal tumors with preoperative virtual navigation using 3D-CT volume-rendering. BMC Urology. 10(1). 7–7. 7 indexed citations

15.

Masuda, Akinori, Takao Kamai, Hideyuki Abe, Kyoko Arai, & Ken‐Ichiro Yoshida. (2009). Is Stat3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma?. Biomedical Research. 30(3). 171–176. 18 indexed citations

16.

Kamai, Takao, Naohisa Tomosugi, Hideyuki Abe, Kyoko Arai, & Ken‐Ichiro Yoshida. (2009). Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer. 9(1). 270–270. 55 indexed citations

17.

Abe, Hideyuki, Takao Kamai, Hiromichi Shirataki, et al.. (2008). High expression of Ran GTPase is associated with local invasion and metastasis of human clear cell renal cell carcinoma. International Journal of Cancer. 122(10). 2391–2397. 58 indexed citations

18.

Abe, Hideyuki, et al.. (2008). Significant association of interleukin 10 receptor mRNA levels with renal cell carcinoma metastasis. Biomedical Research. 29(1). 19–25. 6 indexed citations

19.

Abe, Hideyuki, Takao Kamai, Toshihiko Tsujii, et al.. (2008). Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomedical Research. 29(3). 155–161. 28 indexed citations

20.

Kamai, Takao, Fumitaka Koga, Hideyuki Abe, et al.. (2001). Higher expression of K‐ras is associated with parathyroid hormone‐related protein‐induced hypercalcaemia in renal cell carcinoma. British Journal of Urology. 88(9). 960–966. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact